Cargando…
P2Y(12) Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease
Shunt thrombosis remains a major cause of morbidity and mortality, especially during the initial palliation for single-ventricle physiology. The authors present evidence that the P2Y(12) inhibitor cangrelor may fill a therapeutic void in thromboprophylaxis. They base this theory on results showing t...
Autores principales: | Kaza, Elisabeth A., Egalka, Matthew C., Zhou, Hairu, Chen, Jianchun, Evans, Denise, Prats, Jayne, Li, Ruizhi, Diamond, Scott L., Vincent, Julie A., Bacha, Emile A., Diacovo, Thomas G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646421/ https://www.ncbi.nlm.nih.gov/pubmed/29057376 http://dx.doi.org/10.1016/j.jacbts.2017.04.002 |
Ejemplares similares
-
Admixture lesions in congenital cyanotic heart disease
por: Tharakan, Jaganmohan A
Publicado: (2011) -
Pheochromocytoma in Congenital Cyanotic Heart Disease
por: Aresta, Carmen, et al.
Publicado: (2018) -
Perioperative GABA Blood Concentrations in Infants with Cyanotic and Non-Cyanotic Congenital Heart Diseases
por: Satriano, Angela, et al.
Publicado: (2021) -
COVID-19 in Cyanotic Congenital Heart Disease
por: Ammar, Lama A, et al.
Publicado: (2023) -
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)